89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in MASH

 —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—

—Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval—

https://www.biospace.com/article/releases/89bio-initiates-phase-3-enlighten-cirrhosis-trial-of-pegozafermin-in-metabolic-dysfunction-associated-steatohepatitis-mash-patients-with-compensated-cirrhosis/